Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.
about
Radiation Therapy after Radical Prostatectomy: Implications for CliniciansThe Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsIncorporation of tissue-based genomic biomarkers into localized prostate cancer clinicsMechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerWhat is the Need for Prostatic Biomarkers in Prostate Cancer Management?Prognostic outlier genes for enhanced prostate cancer treatment.Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy.External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancerThe need for a personalized approach for prostate cancer management.A 22 Gene-expression Assay, Decipher® (GenomeDx Biosciences) to Predict Five-year Risk of Metastatic Prostate Cancer in Men Treated with Radical ProstatectomyEvaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasisAssessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use.Decipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patients.Biomarkers for prostate cancer: present challenges and future opportunities.Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies.Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer.Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database.Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality.Clinical Utility of Biomarkers in Localized Prostate Cancer.Early salvage radiation therapy post-prostatectomy: key considerations.Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levelsPRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER.Genomic tests to guide prostate cancer management following diagnosis.Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer.Genomic testing for localized prostate cancer: where do we go from here?Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence.Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy SpecimensIntermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis.Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study.Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients.Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic riskGenetic classifiers for prostate cancer: A new era on the horizon?Prostate cancer radiomics and the promise of radiogenomics.Editorial: Controversies and Perspectives in the Use of Postoperative Radiotherapy for Prostate Cancer.
P2860
Q26744531-3EBA5971-9E35-4CC8-92F3-48DC6E3BB0B4Q26750672-B4E04C94-A08B-40CF-8030-9DC489A8AC24Q26752510-CFEF4069-C55F-4992-A2E9-92F964F7B4CFQ26766638-FF3FB3C6-5102-41A9-9B1C-7C0CA495E9E2Q26798425-20CA0975-B363-4202-B521-D8D71B52B93CQ30244674-8FDF52CD-D51D-4410-9B73-1198ED314AA1Q30385364-240DFD32-B409-41E9-9C4F-1F34E3AF8EDCQ33696684-ED7BD07C-6F71-4E91-A731-3508357ACED2Q35625815-476D930A-7958-4E23-8FF9-B9E07784D608Q35868145-2FDBF4EE-E7DB-4FE7-9E41-A872E691EA49Q37070927-2FFEB9EF-9605-474E-AD36-B2EB3031AF66Q37130232-A3C50970-3209-4371-AAFE-2FCEAF431A7EQ37463713-52AC3B4D-1D07-4CAF-9B32-FC8E15C3C2AFQ37474443-CD4C7AFF-8664-4178-97EF-6C4332661009Q37619763-26F838E5-E106-433C-B2E7-80A6AD7885D1Q37629548-E3543EC3-C7A4-495E-9746-B28B9F3C94F2Q38540198-F33BB16C-C240-498E-8050-850D8A391BB9Q38602697-B6B34E8F-A06A-4107-9A47-784158424390Q38610286-6EF67B2F-9FBD-4491-B996-BC4AC4B2F4F9Q38699141-E9011D35-63D8-4A9C-AB65-416B57DEF683Q38767990-84DCDEA3-F950-4258-B808-A78C1C254A63Q38792354-DFA72DCD-CAC3-4049-B9D9-6EE80C74789EQ38844315-E624550D-4212-4D8E-91D7-211F2FCD7EC5Q38874800-747F4AD9-FBE3-47A8-9364-F2BF7D8EE4ABQ38904571-0ED26C99-A00C-4CC5-8C1E-A66C1C055C73Q39108592-8ECE2678-4641-4FC4-B2A0-55E6362B8904Q39170943-8132C377-B778-47E6-B641-CEDA017F53D7Q39356227-9B2921E1-DBA0-485D-AEA4-484381CAA5FCQ39404903-A9C93AF1-C5B2-46C4-978B-6E07299053ECQ39675735-34A04B12-4334-46B4-8B78-A96E2C648862Q39946238-9CD3ABD5-9B8F-48F7-8D4F-370066118566Q40912174-F6D3F3B0-FBCC-483E-8A2F-A9F90AE93A90Q41418045-ED387101-F51B-49FD-BCD5-F5DE82910001Q41540713-5B77BA60-5E18-45A9-B038-6542EE10AAF8Q41564129-1C0CA8E5-AC0E-4B21-8CBD-1933611964F6Q41612462-0C55CE57-5153-4037-AA28-43ECBCEC8EA5Q42290038-9F447380-FD34-46FE-AB0B-FFF5C1D32DC0Q43190098-1AB3C9D2-D7E9-43DC-94F5-28AAEA6846FAQ47135421-FB9823A9-178E-48C4-9E3C-FBDB2D747D5EQ47137861-6666CDCF-8F8C-4009-BF15-38B5360A2DBA
P2860
Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Genomic classifier identifies ...... om adjuvant radiation therapy.
@en
type
label
Genomic classifier identifies ...... om adjuvant radiation therapy.
@en
prefLabel
Genomic classifier identifies ...... om adjuvant radiation therapy.
@en
P2093
P2860
P50
P356
P1476
Genomic classifier identifies ...... om adjuvant radiation therapy.
@en
P2093
Costas D Lallas
Felix Y Feng
Leonard G Gomella
R Jeffrey Karnes
Voleak Choeurng
P2860
P304
P356
10.1200/JCO.2014.59.0026
P407
P577
2015-02-09T00:00:00Z